Shopping Cart
- Remove All
Your shopping cart is currently empty
Farletuzumab ecteribulin
😃Good
Catalog No. T77908Cas No. 2407465-18-1
Alias MORAb-202
Farletuzumab ecteribulin (MORAb-202) is a highly cytotoxic antibody-drug conjugate (ADC) targeting human folate receptor alpha (FRA). This ADC comprises the humanized Farletuzumab antibody linked to Mal-PEG2-Val-Cit-PAB-eribulin through reduced interchain disulfide bonds, with an agent-to-antibody ratio of 4.0, demonstrating potent antitumor activity against FRA-positive cells in vitro.
Farletuzumab ecteribulin
Farletuzumab ecteribulin
😃Good
Catalog No. T77908Alias MORAb-202Cas No. 2407465-18-1
Farletuzumab ecteribulin (MORAb-202) is a highly cytotoxic antibody-drug conjugate (ADC) targeting human folate receptor alpha (FRA). This ADC comprises the humanized Farletuzumab antibody linked to Mal-PEG2-Val-Cit-PAB-eribulin through reduced interchain disulfide bonds, with an agent-to-antibody ratio of 4.0, demonstrating potent antitumor activity against FRA-positive cells in vitro.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | Inquiry | 8-10 weeks | |
| 5 mg | $3,468 | 8-10 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Farletuzumab ecteribulin"
Trastuzumab deruxtecan
VRN-101099, T-DXd, DS-8201a, DS 8201
T366461826843-81-5
Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.
- $728
Size
QTY
Datopotamab deruxtecan
S-1062a, DS-1062, DS1062, Dato-DXd
T397302238831-60-0
Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.
- $1,060
Size
QTY
IMGC-936, IMGC936
T9901A-084
Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.
- $450
Size
QTY
Disitamab vedotin
RC-48, RC48, RC 48
T395952136633-23-1
Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.
- $347
Size
QTY
Glembatumumab vedotin
CR011-vcMMAE, CR 011 ADC, CDX-011
T741781182215-65-1
Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate with potent anticancer effects, utilized in the study of triple negative breast cancer (TNBC).
- $718
Size
QTY
Sacituzumab govitecan
IMMU-132
T778241491917-83-9
Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.
- $455
Size
QTY
Brentuximab vedotin
SGN-35
T76707914088-09-8
Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.
- $413
Size
QTY
Gemtuzumab ozogamicin
T78047220578-59-6
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a CD33-specific monoclonal antibody linked to a cytotoxic agent derived from Calicheamicin, utilized in the investigation of acute myeloid leukemia [1].
- Inquiry Price
Size
QTY
Enfortumab vedotin-ejfv
T780651346452-25-2
Enfortumab vedotin-ejfv is an antibody-drug conjugate targeting Nectin-4, employed in the treatment of urothelial carcinoma [1].
- $835
Size
QTY
Trastuzumab duocarmazine
(vic)-Trastuzumab duocarmazine
T809551642152-40-6
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is an ADC targeting HER2, cleaved by histone B within tumor cells for selective targeting, exhibiting antitumor activity and applicable in cancer research, particularly for uterine and ovarian sarcomas [1].
- Inquiry Price
Size
QTY
Sofituzumab vedotin
DMUC5754A
T811331418200-58-4
Sofituzumab vedotin (DMUC5754A) is an antibody-drug conjugate (ADC) comprising an anti-MUC16 antibody linked to monomethyl auristatin E (MMAE) via a protease-cleavable linker, utilized for cancer research [1].
- Inquiry Price
Size
QTY
Depatuxizumab MMAE
T82582
Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising the anti-EGFR monoclonal antibody depatuxizumab linked to the cytotoxic agent monomethyl auristatin E (MMAE). This ADC effectively suppresses the growth of xenograft models harboring both mutant EGFRvIII and wild-type EGFR [1].
- Inquiry Price
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Farletuzumab ecteribulin (MORAb-202) is a highly cytotoxic antibody-drug conjugate (ADC) targeting human folate receptor alpha (FRA). This ADC comprises the humanized Farletuzumab antibody linked to Mal-PEG2-Val-Cit-PAB-eribulin through reduced interchain disulfide bonds, with an agent-to-antibody ratio of 4.0, demonstrating potent antitumor activity against FRA-positive cells in vitro. |
| In vitro | Farletuzumab ecteribulin (MORAb-202; 5.1 pM-10 μM; 5 days) demonstrates potent in vitro cytotoxicity against FRA-positive cells (IGROV-1: IC50=1 nM, NCI-H2110: IC50=74 nM, A431-A3: IC50=2.3 μM) [1]. |
| In vivo | Farletuzumab ecteribulin (MORAb-202; intravenous administration; a single injection of 1, 5 mg/kg on Day 0; or injections of 5 mg/kg every 11 days for a total of 2 doses; 60 days) demonstrated significant antitumor activity at one or two doses of 5 mg/kg [1]. With a dosage of 2 mg/kg intravenously, the half-life (T1/2) of farletuzumab ecteribulin on Day 1 was 192 hours in male and 162 hours in female cynomolgus monkeys, with corresponding AUC (0-t) values of 7160 and 6300 µg·h/mL, respectively [1]. |
| Alias | MORAb-202 |
| Cas No. | 2407465-18-1 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Farletuzumab ecteribulin | purchase Farletuzumab ecteribulin | Farletuzumab ecteribulin cost | order Farletuzumab ecteribulin | Farletuzumab ecteribulin in vivo | Farletuzumab ecteribulin in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.